Long‐term follow‐up of alpha‐interferon treatment of patients with chronic hepatitis B

摘要: Data on the long-term effects of interferon alfa (IFN) treatment disease progression and mortality in patients with chronic hepatitis B (CHB) are limited. To evaluate factors that influence clinical outcome survival, we performed a follow-up study 165 e antigen (HBeAg) positive CHB treated IFN between 1978 2002. The median dose was 30 megaunits (MU)/week (range, 2–70 MU/week), duration therapy 16 weeks 1–92 weeks). Response to defined as HBeAg loss within 12 months after end therapy. Median 8.8 years 0.3–24 years). Fifty-four (33%) responded treatment. Relapse (HBeAg reactivation) occurred 7 54 (13%) responders. Fifty-two percent responders lost surface (HBsAg) compared 9% nonresponders (P < .001). Liver histology showed decreased necroinflammatory activity less fibrosis Twenty-six died during follow-up. Hepatocellular carcinoma (HCC) found 8 patients, 6 whom were nonresponders. Of two who developed HCC, one patient had relapsed discontinuation Multivariate analysis significantly improved survival (relative risk (RR) death 0.28, 95% CI 0.10–0.78) reduced developing HCC (RR 0.084, 0.09–0.75) In conclusion, response results prolonged remission an increased rate HBsAg seroconversion liver histology. Our indicate correction for baseline factors, increases reduces HCC. (HEPATOLOGY 2004;39:804–810.)